Flexion Therapeutics (FLXN) Received its Third Buy in a Row
After H.C. Wainwright and Credit Suisse gave Flexion Therapeutics (NASDAQ: FLXN) a Buy rating last month, the company received another Buy, this time from Needham. Analyst Serge Belanger maintained a Buy rating on Flexion Therapeutics today and set a price target of $20.00. The company’s shares closed last Tuesday at $13.06.
According to TipRanks.com, Belanger is a 3-star analyst with an average return of 1.8% and a 43.8% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Amphastar Pharmaceuticals, Collegium Pharmaceutical, and KalVista Pharmaceuticals.
Currently, the analyst consensus on Flexion Therapeutics is a Strong Buy with an average price target of $22.00.
See today’s analyst top recommended stocks >>
Based on Flexion Therapeutics’ latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $15.45 million and GAAP net loss of $32.62 million. In comparison, last year the company earned revenue of $16.95 million and had a GAAP net loss of $36.49 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Flexion Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the development and commercialization of novel and local therapies. It specializes in the treatment of patients with musculoskeletal conditions including osteoarthritis. It offers products under the Zilretta brand. The company was founded by Michael D. Clayman and Neil Bodick in 2007 and is headquartered in Burlington, MA.